Fluxion, Rubicon Team on CTC Applications | GenomeWeb

NEW YORK (GenomeWeb News) – Fluxion Biosciences today said that it has signed a reagent supply and collaboration agreement with Rubicon Genomics aimed at circulating tumor cell applications.

The South San Francisco, Calif.-based firm said that the alliance will integrate enrichment methods for rare cells using Fluxion's IsoFlux System with Rubicon's NovaPlex sample preparation kits.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.